Page 2 - Antibodies in Clinic / Clinical Trials

Bispecific antibodies have emerged as a promising class of therapeutic agents in the field of cancer immunotherapy. As of August 2023, several bispecific antibodies were in various stages of development and clinical trials, showing great potential for improving cancer treatment outcomes.

One of the most notable bispecifics is blinatumomab (Blincyto), a CD19/CD3 bispecific approved for treating acute lymphoblastic leukemia (ALL) that has demonstrated...

1. Background Study

Kidney transplantation is a surgery-based treatment for patients who have prolonged kidney failure or are suffering from chronic or end-stage kidney failure (CKD) [1]. Kidney transplant (KT) procedures in older patients rise daily [2]. The National Kidney Foundation showed that 786,000 patients are living with kidney problems, but only around 25,000 received transplants during 2021 [3]. In the...

1. Background Study

In recent times, many cancerous diseases form of uncontrolled cell division, especially non-small cell lung cancer (NSCLC), melanoma, and breast cancer. Based on statistics from the American Cancer Society, NSCLC accounts for 80% to 85% of all lung cancers [1]. Meanwhile, it is reported that the rate of affected Melanoma skin cancer is 21 per lakh per year, but it causes a significant number...

Exosomal PD-L1 (exoPD-L1) has recently received significant attention as a biomarker predicting immunotherapeutic responses involving the PD1/PD-L1 pathway. However, current technologies for exosomal analysis rely primarily on bulk measurements that do not consider the heterogeneity found within exosomal subpopulations.

A new study presents a nanoscale cytometry platform called NanoEPIC, enabling phenotypic sorting and exoPD-L1 profiling from...

Bispecific antibodies are an emerging and promising class of targeted cancer therapies. These engineered antibodies are able to simultaneously bind to two different antigen targets, allowing for dual targeting of, for example, both a tumor cell and an immune cell (Lee et al. 2022). Over the past year, research has highlighted several key benefits of bispecific antibodies for cancer treatment.

First, bispecific antibodies enable more specific...

Immune checkpoint inhibitors have revolutionized cancer treatment, but response rates remain unsatisfactory in many tumor types. This highlights the need for complementary immunotherapeutic approaches targeting novel pathways beyond PD-1/PD-L1. CD39 has emerged as an exciting inhibitory target – this ectoenzyme generates immunosuppressive adenosine within the tumor microenvironment. Encouragingly, latest research indicates that neutralizing CD39 with...

ichorbio is pleased to announce the release of our first list of all antibodies that are in discovery studies, preclinical and clinical trials. We're currently corresponding with as many biotech firms as we can to add their own candidates into this list. If you see that we're missing yours please contact us at [email protected] and we'll update our data immediately. 

If you'd like to get...